

# Rita Paniccia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6020331/publications.pdf>

Version: 2024-02-01

68  
papers

3,894  
citations

212478

28  
h-index

134545

62  
g-index

68  
all docs

68  
docs citations

68  
times ranked

3740  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of cardiovascular burden on coagulation pathway in apparently healthy women planning oocyte donation. <i>Clinical Hemorheology and Microcirculation</i> , 2021, , 1-9.	0.9	0
2	Platelet Reactivity in Hepatitis C Virusâ€“Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e016441.	1.6	7
3	Clinical Implications of â€œTailoredâ€•Antiplatelet Therapy in Patients With Chronic Total Occlusion. <i>Journal of the American Heart Association</i> , 2020, 9, e014676.	1.6	9
4	Patient blood management in cardiac surgery: The â€œGranducato algorithmâ€•. <i>International Journal of Cardiology</i> , 2019, 289, 37-42.	0.8	26
5	On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 545-552.	0.8	10
6	Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2016, 147, 52-57.	0.8	20
7	High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. <i>European Journal of Internal Medicine</i> , 2016, 30, 49-54.	1.0	17
8	General Aspects of Platelet Function Tests. , 2016, , 35-58.		0
9	Platelet function tests: a comparative review. <i>Vascular Health and Risk Management</i> , 2015, 11, 133.	1.0	356
10	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 76-82.	1.0	27
11	A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. <i>Thrombosis Research</i> , 2015, 136, 613-619.	0.8	4
12	Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndrome. <i>Journal of Cardiology Cases</i> , 2015, 12, 65-67.	0.2	7
13	Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. <i>Thrombosis Research</i> , 2014, 134, 884-888.	0.8	16
14	Assessment of platelet function: Laboratory and point-of-care methods. <i>World Journal of Translational Medicine</i> , 2014, 3, 69.	3.5	7
15	Bioequivalence in the Real World Is a Complex Challenge. <i>Journal of the American College of Cardiology</i> , 2013, 61, 594-595.	1.2	14
16	Perioperative assessment of platelet function by ThromboelastographÂ® Platelet Mappingâ„¢ in cardiovascular patients undergoing non-cardiac surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 23-30.	1.0	34
17	Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. <i>Atherosclerosis</i> , 2013, 231, 392-400.	0.4	43
18	High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. <i>Platelets</i> , 2012, 23, 586-593.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Light Transmittance Aggregometry Induced by Different Concentrations of Adenosine Diphosphate to Monitor Clopidogrel Therapy: A Methodological Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 94-98.	1.0	16
20	Index Measured at an Intermediate Altitude to Predict Impending Acute Mountain Sickness. <i>Medicine and Science in Sports and Exercise</i> , 2011, 43, 1811-1818.	0.2	24
21	High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. <i>Thrombosis and Haemostasis</i> , 2010, 104, 279-286.	1.8	45
22	Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. <i>Thrombosis and Haemostasis</i> , 2010, 104, 587-292.	1.8	64
23	High platelet turnover and reactivity in renal transplant recipients patients. <i>Thrombosis and Haemostasis</i> , 2010, 104, 804-810.	1.8	16
24	Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay. <i>Circulation</i> , 2009, 119, 237-242.	1.6	502
25	Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy. <i>American Journal of Clinical Pathology</i> , 2009, 131, 834-842.	0.4	107
26	<i>e</i> NOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment. <i>Platelets</i> , 2009, 20, 548-554.	1.1	9
27	Assessment of Platelet Function in Whole Blood by Multiple Electrode Aggregometry: Transport of Samples Using a Pneumatic Tube System The Authors'™ Reply. <i>American Journal of Clinical Pathology</i> , 2009, 132, 802-804.	0.4	12
28	Response to Letter Regarding Article, "Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up" • <i>Circulation</i> , 2009, 120, .	1.6	0
29	Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 103, 806-811.	0.7	211
30	Effect of Blood Hematocrit and Erythrocyte Deformability on Adenosine 5'-Diphosphate Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2009, 104, 764-768.	0.7	24
31	Lipid, inflammatory and haemorheological profiles are significantly affected by farmed fish eating: an intervention study. <i>International Journal of Food Sciences and Nutrition</i> , 2009, 60, 50-59.	1.3	8
32	Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2008, 52, 734-739.	1.2	189
33	ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment. <i>Thrombosis Research</i> , 2008, 123, 130-136.	0.8	13
34	Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. <i>Atherosclerosis</i> , 2008, 196, 341-348.	0.4	32
35	Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. <i>Thrombosis and Haemostasis</i> , 2008, 99, 930-935.	1.8	142
36	Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1136-1145.	1.8	41

#	ARTICLE	IF	CITATIONS
37	Comparison of Different Methods to Evaluate the Effect of Aspirin on Platelet Function in High-Risk Patients With Ischemic Heart Disease Receiving Dual Antiplatelet Treatment. <i>American Journal of Clinical Pathology</i> , 2007, 128, 143-149.	0.4	54
38	Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1057-1064.	0.7	204
39	Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. <i>Atherosclerosis</i> , 2007, 195, e217-e223.	0.4	42
40	Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2312-2317.	1.2	607
41	Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. <i>Thrombosis and Haemostasis</i> , 2007, 98, 844-851.	1.8	43
42	Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. <i>Thrombosis and Haemostasis</i> , 2007, 98, 844-51.	1.8	11
43	Usefulness of Aspirin Resistance After Percutaneous Coronary Intervention for Acute Myocardial Infarction in Predicting One-Year Major Adverse Coronary Events. <i>American Journal of Cardiology</i> , 2006, 98, 1156-1159.	0.7	95
44	Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. <i>Clinical Hemorheology and Microcirculation</i> , 2006, 35, 175-81.	0.9	25
45	Point-of-Care Testing of Hemostasis in Cardiac Surgery. , 2003, 1, 1.		51
46	Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2003, 42, 133-139.	1.2	14
47	Evaluation of a New Point-of-care Celite-activated Clotting Time Analyzer in Different Clinical Settings. <i>Anesthesiology</i> , 2003, 99, 54-59.	1.3	38
48	Plasma and serum levels of D-dimer and their correlations with other hemostatic parameters in pregnancy. <i>Thrombosis Research</i> , 2002, 105, 257-262.	0.8	23
49	S-100 Protein and Neuron-Specific Enolase as Markers of Subclinical Cerebral Damage after Cardiac Surgery: Preliminary Observation of a 6-Month Follow-Up Study. <i>European Neurology</i> , 2001, 45, 151-159.	0.6	35
50	Selective Upregulation of Cardiac Endothelin System in Patients With Ischemic but Not Idiopathic Dilated Cardiomyopathy. <i>Circulation Research</i> , 2000, 86, 377-385.	2.0	85
51	Effect of Temperature and Incubation Time on D-Dimer Serum Levels in Healthy Subjects. <i>Thrombosis Research</i> , 2000, 97, 513-517.	0.8	2
52	Endothelin receptors in adult human and swine isolated ventricular cardiomyocytes. <i>Biochemical Pharmacology</i> , 1999, 58, 369-374.	2.0	11
53	Characterization of Endothelin-1 Receptor Subtypes in Isolated Human Cardiomyocytes. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 34, 333-339.	0.8	37
54	Evaluation of Clotting and Fibrinolytic Activation after Protracted Physical Exercise. <i>Thrombosis Research</i> , 1998, 89, 73-78.	0.8	71

#	ARTICLE	IF	CITATIONS
55	Effect of Medium-term Supplementation with a Moderate Dose of n-3 Polyunsaturated Fatty Acids on Blood Pressure in Mild Hypertensive Patients. <i>Thrombosis Research</i> , 1998, 91, 105-112.	0.8	82
56	Increased renal formation of thromboxane A <sub>2</sub> and prostaglandin F <sub>2</sub> ± in heart failure. <i>American Heart Journal</i> , 1997, 133, 94-100.	1.2	25
57	n-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1996, 54, 439-444.	1.0	45
58	Effect of n-3 fatty acid ethyl ester supplementation on fatty acid composition of the single platelet phospholipids and on platelet functions. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 562-569.	1.5	30
59	No changes in PAI-1 levels after four-month n-3 PUFA ethyl ester supplementation in healthy subjects. <i>Thrombosis Research</i> , 1994, 76, 237-244.	0.8	17
60	Binding kinetics and antiplatelet activities of picotamide, a thromboxane A <sub>2</sub> receptor antagonist. <i>British Journal of Pharmacology</i> , 1994, 112, 81-86.	2.7	26
61	Euglobulin Lysis Time in Fresh and Stored Samples. <i>American Journal of Clinical Pathology</i> , 1994, 102, 794-796.	0.4	7
62	Thrombin generation after physical exercise. <i>Thrombosis Research</i> , 1993, 69, 159-164.	0.8	38
63	Effect of Low-Dose Heparin Treatment on Fibrinolysis in Patients with Previous Myocardial Infarction. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1993, 23, 308-313.	0.5	3
64	Age-Related Changes in Red Blood Cell Lipids. <i>Angiology</i> , 1991, 42, 316-322.	0.8	17
65	Relationship between classical FDP test and D-dimer assayed both by latex agglutination and ELISA. <i>Thrombosis Research</i> , 1990, 59, 207-212.	0.8	6
66	Red blood cell lipid alterations in type II diabetes mellitus. <i>Thrombosis Research</i> , 1989, 54, 751-758.	0.8	25
67	Altered lipid composition and thromboxane A <sub>2</sub> formation in platelets from patients affected by IIa hyperlipoproteinemia. <i>Thrombosis Research</i> , 1988, 50, 593-604.	0.8	29
68	Age related changes in platelet lipid composition. <i>Thrombosis Research</i> , 1986, 44, 427-437.	0.8	26